STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available ...
LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report ...
LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, ...
STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor ...
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious ...
The only JAK inhibitor approved in the U.S. for the control of pruritus associated with allergic dermatitis in dogs six months of age and olderRAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known ...
Delivered Q4 and FY2025 revenue above guidanceBest ARR performance of the year in Q4 with total ending ARR of $124 millionRecord percentage of ARR in multi-year agreements and record number of ...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors ...
CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ...
Conference Call and Webcast Scheduled for Thursday, March 5, 2026 at 4:30 PMWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an ...
Total Revenue of $256 Million2025 Software Revenue of $200 Million; 2025 Software ACV of $198 MillionStrong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028Accelerating ...
Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results